Intersect ENT IncFind Ratings Reports
INTERSECT ENT INC's gross profit margin for the second quarter of its fiscal year 2021 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. INTERSECT ENT INC has strong liquidity. Currently, the Quick Ratio is 1.63 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 53.28% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||27.35||9.78|
|Net Income ($mil)||-16.6||-23.12|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||57.86||135.83|
|Total Assets ($mil)||200.86||176.78|
|Total Debt ($mil)||81.43||75.93|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||73.84||74.83|
|Return on Assets||-34.0||-34.76|
|Return on Equity||-164.05||-68.97|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||33.26||32.65|
|Div / share||0.0||0.0|
|Book value / share||1.25||2.73|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||828884.0||228395.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 21.52 indicates a significant premium versus the S&P 500 average of 4.58 and a significant premium versus the subsector average of 10.73. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, INTERSECT ENT INC proves to trade at a premium to investment alternatives.
|XENT NM||Peers 80.34||XENT NM||Peers 47.25|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
XENT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
XENT's P/CF is negative making the measure meaningless.
|XENT NM||Peers 70.05||XENT NA||Peers 0.59|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
XENT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|XENT 21.52||Peers 10.73||XENT -8.90||Peers 170.99|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
XENT is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, XENT is expected to significantly trail its peers on the basis of its earnings growth rate.
|XENT 8.73||Peers 14.80||XENT 20.14||Peers 25.93|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
XENT is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
XENT trails its peers on the basis of sales growth.